View Older Stories View More Recent Stories

Nov 10, 2017 04:16PM BMS (BMY)-Pfizer (PFE) Alliance to Unveil Real-World Data Analyses Associated with Oral Anticoagulants in NVAF
Nov 10, 2017 04:13PM BMS-Pfizer Alliance to Unveil Real-World Data Analyses - Cost, Safety and Comparative Effectiveness Findings Associated with Oral Anticoagulants in Non-Valvular Atrial Fibrillation
Nov 10, 2017 07:01AM Bristol-Myers Squibb (BMY) Says Encouraging Response Observed with Opdivo Plus Investigational IDO1 Inhibitor, BMS-986205, in Heavily Pre-Treated Patients with Advanced Cancers in Phase 1/2a Study CA0
Nov 10, 2017 07:00AM Encouraging Response Observed with Opdivo (nivolumab) Plus Investigational IDO1 Inhibitor, BMS-986205, in Heavily Pre-Treated Patients with Advanced Cancers in Phase 1/2a Study CA017-003
Nov 10, 2017 06:31AM Bristol-Myers Squibb (BMY) Announces FDA Expanded Approval for Sprycel to Include Children with Ph+ CML in Chronic Phase
Nov 10, 2017 06:30AM U.S. Food and Drug Administration Expands Approval of Sprycel® (dasatinib) to Include Treatment of Children with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase
Nov 9, 2017 08:09AM Bristol-Myers Squibb (BMY) & Five Prime (FPRX) Announce Phase 1a/1b Data Evaluating Cabiralizumab (anti-CSF-1 receptor antibody) with Opdivo (nivolumab) in Patients with Advanced Solid Tumors
Nov 9, 2017 08:00AM Bristol-Myers Squibb and Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab (anti-CSF-1 receptor antibody) with Opdivo (nivolumab) in Patients with Advanced Solid Tumors
Nov 8, 2017 06:59AM Bristol-Myers Squibb to Take Part in Jefferies London Healthcare Conference
Nov 7, 2017 08:35AM Opdivo Plus Yervoy Combination Delivered Overall Survival Benefit Across PD-L1 Expression Levels in Intermediate- and Poor-Risk Patients with Previously Untreated Advanced or Metastatic Renal Cell Car
Nov 7, 2017 08:01AM Bristol-Myers Squibb (BMY) to Highlight Clinical and Translational Research at SITC
Nov 7, 2017 08:00AM Bristol-Myers Squibb to Highlight Clinical and Translational Research at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting
Nov 6, 2017 06:59AM Opdivo (nivolumab) Demonstrates Superior Three-Year Survival Benefit for Patients with Previously Treated Advanced Renal Cell Carcinoma (RCC)
Nov 2, 2017 08:17AM Bristol-Myers Squibb (BMY) to Showcase Progress in Researching Personalized Medicine for Potential Treatment of Autoimmune Diseases at ACR/ARHP Meeting
Nov 2, 2017 06:59AM Bristol-Myers Squibb to Showcase Company’s Progress in Researching Personalized Medicine for the Potential Treatment of Autoimmune Diseases at 2017 American College of Rheumatology and Association o
Nov 1, 2017 06:59AM Bristol-Myers Squibb, BioLabs Announce Founding Sponsorship in Support of Promising Biotech Companies in New York
Oct 30, 2017 07:00AM Bristol-Myers Squibb (BMY) Reports EMA Validates Type II Variation Application for Opdivo (Nivolumab)
Oct 30, 2017 06:59AM European Medicines Agency Validates Bristol-Myers Squibb’s Type II Variation Application for Opdivo (nivolumab) for Treatment of Patients with Resected High-Risk Advanced Melanoma
Oct 26, 2017 06:59AM Bristol-Myers Squibb Reports Third Quarter Financial Results
Oct 25, 2017 07:41AM Dow, S&P gain but Nasdaq dips as healthcare lags
Oct 20, 2017 06:59AM Bristol-Myers Squibb to Present New Data Advancing Research Across Serious Liver Diseases at The Liver Meeting® 2017
Oct 16, 2017 04:22PM Bristol-Myers Squibb (BMY) Says FDA Accepted its Application for Opdivo in Patients with Resected High-Risk Advanced Melanoma and Grants Priority Review
Oct 16, 2017 04:15PM U.S. Food and Drug Administration (FDA) Accepts Bristol-Myers Squibb’s Application for Opdivo (nivolumab) in Patients with Resected High-Risk Advanced Melanoma and Grants Priority Review
Oct 16, 2017 03:15AM Opdivo Alone or Combined with Yervoy Shows Encouraging Response and Survival Rates in Recurrent Small Cell Lung Cancer Patients with High Tumor Mutation Burden, in Exploratory Analysis from Phase 1/2
Oct 9, 2017 06:59AM Bristol-Myers Squibb Appoints Saurabh Saha, M.D., Ph.D., as Senior Vice President, Global Head of Translational Medicine
Oct 4, 2017 06:59AM Caregivers Wish Liver Cancer Received Greater Public Awareness in the U.S., New Survey Reveals
Sep 27, 2017 05:07PM Bristol-Myers Squibb (BMY) Announces Presentations at IASLC
Sep 27, 2017 05:00PM Bristol-Myers Squibb: Advancing Research Across Thoracic Cancers with New Data at IASLC 18th World Conference on Lung Cancer
Sep 25, 2017 05:37AM Bristol-Myers Squibb (BMY) Granted FDA Approval for Opdivo for Treatment of Hepatocellular Carcinoma Patients
Sep 22, 2017 06:10PM Bristol-Myers Squibb’s Opdivo® (nivolumab) Receives FDA Approval for the Treatment of Hepatocellular Carcinoma Patients Previously Treated with Sorafenib
Sep 22, 2017 07:01AM AbbVie (ABBV), Bristol-Myers Squibb (BMY) Announce Pact to Evaluate Therapeutic Regimen in Advanced Solid Tumors
Sep 22, 2017 07:00AM AbbVie and Bristol-Myers Squibb Announce Clinical Research Collaboration to Evaluate a Therapeutic Regimen in Advanced Solid Tumors
Sep 22, 2017 06:59AM AbbVie and Bristol-Myers Squibb Announce Clinical Research Collaboration to Evaluate a Therapeutic Regimen in Advanced Solid Tumors
Sep 22, 2017 05:40AM Bristol-Myers Squibb (BMY) Granted Approval by Japanese Ministry of Health for Opdivo (nivolumab) Based on 3 Study ATTRACTION-2 (ONO-4538-12)
Sep 22, 2017 05:00AM Japan Ministry of Health, Labor and Welfare Approves Opdivo (nivolumab) for the Treatment of Patients with Unresectable Advanced or Recurrent Gastric Cancer Which Has Progressed After Chemotherapy
Sep 21, 2017 06:59AM Bristol-Myers Squibb to Take Part in Leerink Partners Rare Disease & Immuno-Oncology Roundtable Conference
Sep 21, 2017 06:59AM New Global Report Finds Majority of People at High Risk of Stroke Not Being Screened for Common Risk Factors
Sep 14, 2017 07:00AM Bristol-Myers Squibb (BMY), Halozyme (HALO) Enter Pact for ENHANZE Technology
Sep 14, 2017 06:59AM Bristol-Myers Squibb and Halozyme Enter Global Collaboration and License Agreement for ENHANZE Technology
Sep 13, 2017 04:30PM Bristol-Myers Squibb Announces Dividend
Sep 13, 2017 04:16PM Bristol-Myers Squibb (BMY) Names Karen Vousden to Board of Directors
Sep 13, 2017 04:15PM Bristol-Myers Squibb Names Karen Vousden, Ph.D. to Board of Directors
Sep 11, 2017 06:21AM Bristol-Myers Squibb (BMY) Reports Opdivo (nivolumab) Demonstrates Superior Recurrence-Free Survival Versus Yervoy (ipilimumab) in Phase 3 CheckMate -238 Study
Sep 11, 2017 06:16AM Bristol-Myers Squibb (BMY) Reports Opdivo Plus Yervoy Combination Demonstrated Superior Overall Survival in Phase 3 CheckMate -214 Trial
Sep 10, 2017 06:11PM Opdivo (nivolumab) Demonstrates Superior Recurrence-Free Survival Versus Yervoy (ipilimumab) for Patients with Resected High-Risk Melanoma in Phase 3 CheckMate -238 Study
Sep 10, 2017 11:55AM Opdivo Plus Yervoy Combination Demonstrated Superior Overall Survival and Showed Durable Responses in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma in Phase 3 CheckMat
Sep 8, 2017 05:49AM Bristol-Myers Squibb (BMY) Reports Two Pivotal Opdivo (nivolumab) Trials Show Three-Year Survival Benefit in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer
Sep 8, 2017 05:30AM Two Pivotal Opdivo (nivolumab) Trials Show Three-Year Survival Benefit in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer
Sep 7, 2017 04:30PM Bristol-Myers Squibb Completes Previously Announced Acquisition of IFM Therapeutics
Sep 7, 2017 07:02AM Bristol-Myers Squibb (BMY) Reports CheckMate-214 Study Evaluating Opdivo in Combination with Yervoy Meets Co-Primary Endpoint, Demonstrating Superior Overall Survival Compared to Sunitinib
View More Recent Stories View Older Stories